Arcus Biosciences Inc (RCUS)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -301,000 | -266,000 | 55,000 | -156,800 | -104,410 |
| Revenue | US$ in thousands | 117,000 | 112,000 | 382,882 | 77,517 | 15,000 |
| Pretax margin | -257.26% | -237.50% | 14.36% | -202.28% | -696.07% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-301,000K ÷ $117,000K
= -257.26%
Arcus Biosciences Inc's pretax margin, as reflected in the data provided, has shown significant fluctuations over the past five years. In 2019, the company experienced a notably low pretax margin of -564.73%, indicating a substantial loss before tax. This was followed by a further negative trend in 2020, where the pretax margin improved slightly to -158.49%, but remained in negative territory.
However, a positive turn was observed in 2021, with the pretax margin increasing to 14.27%, signaling a return to profitability before tax for Arcus Biosciences Inc. Nonetheless, this positive momentum appears to have been short-lived as the pretax margin sharply declined to -237.50% in 2022, indicating a reversal back to losses prior to tax.
The most recent data point for 2023 reveals a significant deterioration in the company's financial performance, with a substantial pretax margin of -257.26%, marking a return to high levels of pre-tax losses. Overall, the erratic nature of Arcus Biosciences Inc's pretax margin over the past five years suggests a volatile financial performance, highlighting potential challenges in sustaining profitability in the long term.
Peer comparison
Dec 31, 2023